- Home
- KNOP vs FHTX Comparison
KNOP vs FHTX Comparison
Compare KNOP & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KNOP | FHTX |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 366.5M | 360.8M |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | KNOP | FHTX |
|---|---|---|
| Price | $10.48 | $5.57 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | N/A | ★ $11.43 |
| AVG Volume (30 Days) | 109.6K | ★ 199.4K |
| Earning Date | 12-04-2025 | 03-05-2026 |
| Dividend Yield | ★ 1.00% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.17 | N/A |
| Revenue | ★ $352,712,000.00 | $24,518,000.00 |
| Revenue This Year | $14.84 | $40.91 |
| Revenue Next Year | $1.98 | $11.87 |
| P/E Ratio | $8.90 | ★ N/A |
| Revenue Growth | ★ 17.65 | N/A |
| 52 Week Low | $5.29 | $2.95 |
| 52 Week High | $11.10 | $6.95 |
Technical Indicators
Market Signals| Indicator | KNOP | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.02 | 52.29 |
| Support Level | $10.06 | $5.89 |
| Resistance Level | $11.10 | $6.95 |
| Average True Range (ATR) | 0.27 | 0.49 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 40.38 | 40.26 |
Price Performance
Historical ComparisonAbout KNOP KNOT Offshore Partners LP
KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.